Clinical trials
Terminated Acquired Immunodeficiency Syndrome trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
78 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 5 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 5 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 78 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 10 |
| ViiV Healthcare | 7 |
| GlaxoSmithKline | 3 |
| National Cancer Institute (NCI) | 3 |
| Emory University | 2 |
| Gilead Sciences | 2 |
| National Institutes of Health Clinical Center (CC) | 2 |
| Virginia Commonwealth University | 2 |
| Boston Medical Center | 1 |
| Centers for Disease Control and Prevention | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Acquired Immunodeficiency Syndrome | 78 |
| HIV Infections | 30 |
| Infections | 8 |
| Hepatitis C | 6 |
| Sexually Transmitted Diseases | 4 |
| AIDS-Related Complex | 3 |
| AIDS-Related Opportunistic Infections | 3 |
| Diabetes Mellitus | 2 |
| Hypertension | 2 |
| Lung Diseases | 2 |
Trials
Showing 1 to 25 of 78. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.